COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Use of Erythromycin in Mustard-Induced Bronchiolitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00367419
Recruitment Status : Completed
First Posted : August 22, 2006
Last Update Posted : November 5, 2008
Information provided by:
Baqiyatallah Medical Sciences University

Brief Summary:
We looked for the effectiveness of low-dose long-term prescription of erythromycin in mustard-induced bronchiolitis obliterans

Condition or disease Intervention/treatment Phase
Bronchiolitis Obliterans Acute Obliterating Bronchiolitis Drug: Erythromycin Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Low-Dose Long-Term Prescription of Erythromycin in Mustard-Induced Bronchiolitis Obliterans

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   Male

Inclusion Criteria:

  • Documented chemical exposure
  • Clinical, spirometric and radiological findings were compatible with BO on High Resolution Computed Tomography (HRCT)
  • Non-responsiveness to high dose bronchodilator therapy

Exclusion Criteria:

  • Radiographic evidence of pneumonia, active tuberculosis, lung carcinoma, or an infection that necessitated the use of an antibiotic
  • History of cigarette smoking and occupational exposure to toxic agents of hypersensitivity to macrolides
  • History of treatment with a systemic antibiotic within 7 days before the start of the study
  • Any investigational medicine within 4 weeks of the study
  • History of antibiotic injection within 6 weeks before the study
  • Concomitant Theophylline or Carbamazepine, unless their serum concentrations were regularly monitored
  • Patients who were in the exacerbation phase of their respiratory complications
  • Need to use medications interact with macrolides such as Digoxin, Theophylline and Carbamazepine
  • Systemic antibiotics
  • Systemic Corticosteroids
  • Admission to the hospital
  • Abnormal kidney or liver function

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00367419

Layout table for location information
Iran, Islamic Republic of
Baqiyatallah Medical Sciences University
Tehran, Iran, Islamic Republic of, 19945-546
Sponsors and Collaborators
Baqiyatallah Medical Sciences University
Layout table for investigator information
Study Director: Mostafa Ghanei, Professor Research Center of Chemical Injuries, Baqyatallah Medical Sciences University, Tehran, Iran

Layout table for additonal information Identifier: NCT00367419    
Other Study ID Numbers: S-340-14-6-1-PU-02
First Posted: August 22, 2006    Key Record Dates
Last Update Posted: November 5, 2008
Last Verified: March 2006
Additional relevant MeSH terms:
Layout table for MeSH terms
Bronchiolitis Obliterans
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Tract Infections
Erythromycin Estolate
Erythromycin Ethylsuccinate
Erythromycin stearate
Molecular Mechanisms of Pharmacological Action
Anti-Bacterial Agents
Anti-Infective Agents
Gastrointestinal Agents
Protein Synthesis Inhibitors
Enzyme Inhibitors